The news: GoodRx is launching a weight loss telehealth membership plan and discounting the cash-pay price for Novo Nordisk’s Ozempic and Wegovy.

• GoodRx’s weight loss plan costs $39 per month until Feb. 1, 2026, when it will increase to $119. It includes telehealth healthcare provider consultations and ongoing support; medication costs for Eli Lilly or Novo Nordisk drugs are separate.
• GoodRx is also offering a discount for the cash-pay price of lower-dose Ozempic and Wegovy at $199 for the first two months on the plan. The discount extends to the pharmacy counter for consumers with an existing prescription.

Why it matters: GoodRx is expanding its telehealth reach and tapping into rising consumer interest in GLP-1 medications.

• The new membership plans build on GoodRx’s June erectile dysfunction and October men’s hair loss direct-to-consumer (D2C) subscription plans.
• GLP-1 use doubled in the past 18 months—12% of US adults are currently taking them compared with 6% in May 2024, per KFF surveying.
• KFF also reports that 22% of all adults who are not taking GLP-1s are interested in trying them for weight loss. And 43% who have been diagnosed as overweight or obese within the past five years are interested in GLP-1s.

Implications for telehealth: GoodRx is newer to telehealth, but already making waves and forging closer relationships with drugmakers. A key message in its launch is that it won’t offer compounded medications, unlike Hims & Hers, Noom, and other smaller players. Competitors like Ro and WeightWatchers also avoid compounded versions and offer similar $199 low-dose starter pricing, but none have GoodRx’s in-store pharmacy ties. Combined with strong brand recognition, healthcare provider connections, and 30 million active users, GoodRx has an advantage for now.

As price competition heats up, however, telehealth players will need more than discounts. Long-term success will rely on marketing, easy onboarding, support tools and adherence encouragement, and delivering consistent, trusted consumer experiences.

Implications for GLP-1 drugmakers: Every new telehealth partnership broadens access for Lilly and Novo, and increases pressure on future GLP-1 drugmakers to secure similar deals.

Both companies are also responding to consumer and Trump administration pricing demands, such as agreeing to drop GLP-1 drug pricing to around $350 per month on the TrumpRx platform set to launch in January—but pricing is just one consideration. With oral GLP-1 options expected to arrive next year, the GLP-1 market will become even more competitive, raising consumer expectations for both cost and convenience.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.